Long COVID Trial, Recruiting NCT06825819 Sponsor: University of Chicago Condition: Long COVID
Back to Long Covid

Long COVID Trial, Recruiting

NCT06825819
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 80 years old
  • You had a confirmed COVID-19 infection (by PCR or antigen test) within the past 3 years that caused symptoms
  • You may or may not have received a COVID-19 vaccine
  • You may or may not currently have long COVID symptoms (such as digestive, heart, lung, brain, muscle, or mental health issues)
  • You may or may not already be scheduled for a routine endoscopy at the University of Chicago Medicine

Who may not be able to join:

  • You are younger than 18 or older than 80
  • Your last confirmed COVID-19 infection was more than 3 years ago
  • You have recently tested positive for COVID-19 in the last 3 months
  • You currently have a cancer diagnosis
  • You are currently pregnant (though you may still be eligible for parts of the study involving surveys, blood, or stool collection — confirm with trial site)
  • You are currently taking or have recently taken certain immune-suppressing medications called "biologics"
  • You have an official diagnosis of inflammatory bowel disease (IBD) or another long-term digestive condition

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Lavanya Visvabharathy, Ph.D, University of Chicago

Phone: 773-834-5087

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
21 January 2025
Est. completion
1 January 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

To determine whether people with long COVID exhibit microbial dysbiosis characterized by decreased bacterial diversity, overgrowth of Bacteroides taxa, and lower SCFA, indole, and secondary bile acid production with biospecimen collections

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov